 |
(Photo= Yonhap news) |
[Alpha Biz= Reporter Kim Jisun] Hanmi Science, the holding company of the Hanmi Pharmaceutical Group, announced on the 2nd that it has filed a request with the court to approve the convening of a special shareholders' meeting for Hanmi Pharmaceutical.
This request comes just two days after Hanmi Science proposed holding the special meeting to vote on the dismissal of Hanmi Pharmaceutical CEO Park Jae-hyun and Shin Dong-guk, chairman of Hanyang Precision, from their board positions.
In response, Hanmi Pharmaceutical raised concerns, suggesting that this might be a unilateral decision by Hanmi Science CEO Lim Jong-hoon. Hanmi Pharmaceutical argued, "The request for a special shareholders' meeting is an important business matter under the Commercial Act, requiring a resolution by the board of directors. Hanmi Science’s board regulations clearly state that lawsuits against major subsidiaries, such as the dismissal of directors, must be approved by the board."
Hanmi Pharmaceutical further noted, "The special shareholders' meeting held last May was conducted following a resolution by Hanmi Science's board of directors. If the request for court approval was made unilaterally by the CEO without board approval, it raises procedural concerns. We urge efforts to address these concerns first."
Currently, a conflict is ongoing between Hanmi Science's internal directors, including CEO Lim Jong-hoon and Executive Director Lim Jong-yoon, and other figures such as Shin Dong-guk, Hanmi Pharmaceutical Group Chairwoman Song Young-sook, and Vice Chairwoman Lim Joo-hyun, who are advocating for a transition to a professional management system.
Alphabiz Reporter Kim Jisun(stockmk2020@alphabiz.co.kr)
